CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 44.44%

Compliant submissions 4

Incompliant submissions 5

Total trials 9

My Organizations' Clinical Trials

Showing 100 of 430 entries

View as:

Ketamine for Suicidality in Bipolar Depression

Phase: N/A Priority: Normal

NCT ID: NCT01944293 Org: User:

Start: 09/30/13 End: 10/31/18 Due: 10/31/19

Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks

Phase: N/A Priority: Normal

NCT ID: NCT00373399 Org: User:

Start: 05/31/06 End: 03/31/08 Due: 03/31/09

Treatment Outcome in CBT for Cocaine Use

Phase: N/A Priority: Normal

NCT ID: NCT03538548 Org: User:

Start: 09/30/14 End: 07/31/21 Due: 07/31/22

Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals

Phase: N/A Priority: Normal

NCT ID: NCT03711318 Org: User:

Start: 11/01/18 End: 12/31/21 Due: 12/31/22

A Neurocognitive Model of Anorexia Nervosa

Phase: N/A Priority: Normal

NCT ID: NCT00325520 Org: User:

Start: 05/31/06 End: 05/31/14 Due: 05/31/15

Exercise and Olanzapine-samidorphan

Phase: N/A Priority: Normal

NCT ID: NCT06740890 Org: User:

Start: 06/15/25 End: 04/30/27 Due: 04/30/28

Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa

Phase: N/A Priority: Normal

NCT ID: NCT01170117 Org: User:

Start: 08/31/10 End: 06/30/17 Due: 06/30/18

A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence

Phase: N/A Priority: Normal

NCT ID: NCT00421603 Org: User:

Start: 02/28/07 End: 05/31/10 Due: 05/31/11

Dichotic Listening as a Predictor of Medication Response in Depression

Phase: N/A Priority: Normal

NCT ID: NCT00296725 Org: User:

Start: 04/30/94 End: 06/30/11 Due: 06/30/12

Add-on Simvastatin in Schizophrenia Trial

Phase: N/A Priority: Normal

NCT ID: NCT00605995 Org: User:

Start: 02/29/08 End: 08/31/11 Due: 08/31/12

Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence

Phase: N/A Priority: Normal

NCT ID: NCT01467999 Org: User:

Start: 02/29/12 End: 10/31/16 Due: 10/31/17

Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

Phase: N/A Priority: Normal

NCT ID: NCT03278938 Org: User:

Start: 06/29/12 End: 01/31/16 Due: 01/31/17

Effect of Quetiapine on Marijuana Withdrawal and Relapse

Phase: N/A Priority: Normal

NCT ID: NCT00743366 Org: User:

Start: 08/31/08 End: 03/31/09 Due: 03/31/10

Reducing Stigma and Increasing Treatment Seeking Intentions Among Adolescents

Phase: N/A Priority: Normal

NCT ID: NCT06222528 Org: User:

Start: 06/03/24 End: 08/17/24 Due: 08/17/25

Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression

Phase: N/A Priority: Normal

NCT ID: NCT01754493 Org: User:

Start: 12/31/08 End: 12/31/14 Due: 12/31/15

Reducing Depression Self-stigma and Increasing Treatment Seeking Intentions Among Youth

Phase: N/A Priority: Normal

NCT ID: NCT06172075 Org: User:

Start: 04/15/24 End: 05/29/24 Due: 05/29/25

TDCS for Auditory Hallucinations in Schizophrenia

Phase: N/A Priority: Normal

NCT ID: NCT01898299 Org: User:

Start: 05/31/13 End: 08/14/18 Due: 08/14/19

Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence

Phase: N/A Priority: Normal

NCT ID: NCT01468012 Org: User:

Start: 07/31/14 End: 12/31/15 Due: 12/31/16

Personalized and Scalable Cognitive Remediation Approaches

Phase: N/A Priority: Normal

NCT ID: NCT01945333 Org: User:

Start: 09/30/13 End: 03/20/19 Due: 03/20/20

Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

Phase: N/A Priority: Normal

NCT ID: NCT02034474 Org: User:

Start: 02/28/14 End: 02/06/17 Due: 02/06/18

Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)

Phase: N/A Priority: Normal

NCT ID: NCT02422290 Org: User:

Start: 03/31/15 End: 07/31/20 Due: 07/31/21

An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder

Phase: N/A Priority: Normal

NCT ID: NCT03861338 Org: User:

Start: 03/01/19 End: 02/28/20 Due: 02/28/21

PET Biomarkers in Treatment Resistant Depression

Phase: N/A Priority: Normal

NCT ID: NCT01031810 Org: User:

Start: 11/30/09 End: 03/31/13 Due: 03/31/14

Pregabalin as Treatment for Alcohol Use Disorder

Phase: N/A Priority: Normal

NCT ID: NCT03256253 Org: User:

Start: 02/15/18 End: 05/31/20 Due: 05/31/21

Duloxetine for Chronic Depression: a Double-blind Study

Phase: N/A Priority: Normal

NCT ID: NCT00360724 Org: User:

Start: 08/31/06 End: 12/31/13 Due: 12/31/14

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Ketamine for Suicidality in Bipolar Depression	NCT01944293	New York State Psychiatric Institute	user2@example.com	None	2013-09-30	2018-10-31	2019-10-31	-	-	2025-07-14
Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks	NCT00373399	New York State Psychiatric Institute	user2@example.com	None	2006-05-31	2008-03-31	2009-03-31	-	-	2025-07-14
Treatment Outcome in CBT for Cocaine Use	NCT03538548	New York State Psychiatric Institute	user2@example.com	None	2014-09-30	2021-07-31	2022-07-31	-	-	2025-07-14
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals	NCT03711318	New York State Psychiatric Institute	user2@example.com	None	2018-11-01	2021-12-31	2022-12-31	-	-	2025-07-14
A Neurocognitive Model of Anorexia Nervosa	NCT00325520	New York State Psychiatric Institute	user2@example.com	None	2006-05-31	2014-05-31	2015-05-31	-	-	2025-07-14
Exercise and Olanzapine-samidorphan	NCT06740890	New York State Psychiatric Institute	user2@example.com	None	2025-06-15	2027-04-30	2028-04-30	-	-	2025-07-14
Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa	NCT01170117	New York State Psychiatric Institute	user2@example.com	None	2010-08-31	2017-06-30	2018-06-30	-	-	2025-07-14
A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence	NCT00421603	New York State Psychiatric Institute	user2@example.com	None	2007-02-28	2010-05-31	2011-05-31	-	-	2025-07-14
Dichotic Listening as a Predictor of Medication Response in Depression	NCT00296725	New York State Psychiatric Institute	user2@example.com	None	1994-04-30	2011-06-30	2012-06-30	-	-	2025-07-14
Add-on Simvastatin in Schizophrenia Trial	NCT00605995	New York State Psychiatric Institute	user2@example.com	None	2008-02-29	2011-08-31	2012-08-31	-	-	2025-07-14
Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence	NCT01467999	New York State Psychiatric Institute	user2@example.com	None	2012-02-29	2016-10-31	2017-10-31	-	-	2025-07-14
Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders	NCT03278938	New York State Psychiatric Institute	user2@example.com	None	2012-06-29	2016-01-31	2017-01-31	-	-	2025-07-14
Effect of Quetiapine on Marijuana Withdrawal and Relapse	NCT00743366	New York State Psychiatric Institute	user2@example.com	None	2008-08-31	2009-03-31	2010-03-31	-	-	2025-07-14
Reducing Stigma and Increasing Treatment Seeking Intentions Among Adolescents	NCT06222528	New York State Psychiatric Institute	user2@example.com	None	2024-06-03	2024-08-17	2025-08-17	-	-	2025-07-14
Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression	NCT01754493	New York State Psychiatric Institute	user2@example.com	None	2008-12-31	2014-12-31	2015-12-31	-	-	2025-07-14
Reducing Depression Self-stigma and Increasing Treatment Seeking Intentions Among Youth	NCT06172075	New York State Psychiatric Institute	user2@example.com	None	2024-04-15	2024-05-29	2025-05-29	-	-	2025-07-14
TDCS for Auditory Hallucinations in Schizophrenia	NCT01898299	New York State Psychiatric Institute	user2@example.com	None	2013-05-31	2018-08-14	2019-08-14	-	-	2025-07-14
Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence	NCT01468012	New York State Psychiatric Institute	user2@example.com	None	2014-07-31	2015-12-31	2016-12-31	-	-	2025-07-14
Personalized and Scalable Cognitive Remediation Approaches	NCT01945333	New York State Psychiatric Institute	user2@example.com	None	2013-09-30	2019-03-20	2020-03-20	-	-	2025-07-14
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia	NCT02034474	New York State Psychiatric Institute	user2@example.com	None	2014-02-28	2017-02-06	2018-02-06	-	-	2025-07-14
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)	NCT02422290	New York State Psychiatric Institute	user2@example.com	None	2015-03-31	2020-07-31	2021-07-31	-	-	2025-07-14
An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder	NCT03861338	New York State Psychiatric Institute	user2@example.com	None	2019-03-01	2020-02-28	2021-02-28	-	-	2025-07-14
PET Biomarkers in Treatment Resistant Depression	NCT01031810	New York State Psychiatric Institute	user2@example.com	None	2009-11-30	2013-03-31	2014-03-31	-	-	2025-07-14
Pregabalin as Treatment for Alcohol Use Disorder	NCT03256253	New York State Psychiatric Institute	user2@example.com	None	2018-02-15	2020-05-31	2021-05-31	-	-	2025-07-14
Duloxetine for Chronic Depression: a Double-blind Study	NCT00360724	New York State Psychiatric Institute	user2@example.com	None	2006-08-31	2013-12-31	2014-12-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance